A team of University of Houston pharmaceutical researchers is reporting a newly recognized process of drug metabolism in the intestines - followed by recycling through the liver - that could have important implications for developing treatments for intestinal diseases and for taking multiple medications at the same time.
More doesn't necessarily mean better - including in cancer treatment. University of Pittsburgh School of Medicine and University of Wisconsin-Madison scientists report today in Science Translational Medicine that combining targeted radiopharmaceutical therapy with immunotherapy significantly boosts eradication of metastatic cancer in mice, even when the radiation is given in doses too low to destroy the cancer outright.
Researchers in the University of Arizona Health Sciences Comprehensive Pain and Addiction Center have found that terpenes mimic cannabinoids and produce similar pain-relieving effects, which are amplified when the two are used together.
Solving structures of potential therapeutics using X-ray diffraction (XRD) is usually a pivotal step in drug development. But XRD generally requires large, well-ordered crystals. Advancements in automated data collection and processing have increased interest in electron diffraction as an XRD alternative. Electron diffraction uses a beam of electrons rather than X-rays to obtain structures. Here researchers present a new drug development pipeline using electron diffraction for use when XRD may not be an option.
Scientists at Tokyo Institute of Technology have developed a computational method based on large-scale molecular dynamics simulations to predict the cell-membrane permeability of cyclic peptides using a supercomputer. Their protocol has exhibited promising accuracy and may become a useful tool for the design and discovery of cyclic peptide drugs, which could help us reach new therapeutic targets inside cells beyond the capabilities of conventional small-molecule drugs or antibody-based drugs.
According to ARRS' American Journal of Roentgenology, among the 78 patients with cancer who underwent standard-dose chest CT and reduced-dose chest CT in the same imaging encounter, the reduced-dose protocol detected greater than 90% of lung nodules identified on the standard-dose examination.
Dmitri Simberg, PhD, associate professor in the University of Colorado Skaggs School of Pharmacy, released the results of a study of the effectiveness of different types of fluorescent labels used to monitor the accumulation of liposomes in tumors. The study, titled "Liposomal Extravasation and Accumulation in Tumors as Studied by Fluorescence Microscopy and Imaging Depend on the Fluorescent Label," was published on July 1, 2021, in the journal of the American Chemical Society, ACS Nano.
The body is filled with mucus that keeps track of the bacteria. Now, researchers from the University of Copenhagen present the first method for producing artificial mucus. They hope that the artificial mucus, which consists of sugary molecules, may help to develop completely new, medical treatments.
Artificial intelligence (AI) is able to recognise the biological activity of natural products in a targeted manner, as researchers at ETH Zurich have demonstrated. Moreover, AI helps to find molecules that have the same effect as a natural substance but are easier to manufacture. This opens up huge possibilities for drug discovery, which also have potential to rewrite the rulebook for pharmaceutical research.
A small fungal enzyme could play a significant role in simplifying the development and manufacture of drugs, according to Rice University scientists.